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Abstract
Alpha-synuclein, the major component of Lewy bodies, is thought to play a central role in the onset of synaptic
dysfunctions in Parkinson’s disease (PD). In particular, a-synuclein may affect dopaminergic neuron function as it interacts
with a key protein modulating dopamine (DA) content at the synapse: the DA transporter (DAT). Indeed, recent evidence
from our ‘‘in vitro’’ studies showed that a-synuclein aggregation decreases the expression and membrane trafficking of the
DAT as the DAT is retained into a-synuclein-immunopositive inclusions. This notwithstanding, ‘‘in vivo’’ studies on PD
animal models investigating whether DAT distribution is altered by the pathological overexpression and aggregation of a-
synuclein are missing. By using the proximity ligation assay, a technique which allows the ‘‘in situ’’ visualization of protein-
protein interactions, we studied the occurrence of alterations in the distribution of DAT/a-synuclein complexes in the
SYN120 transgenic mouse model, showing insoluble a-synuclein aggregates into dopaminergic neurons of the nigrostriatal
system, reduced striatal DA levels and an altered distribution of synaptic proteins in the striatum. We found that DAT/a-
synuclein complexes were markedly redistributed in the striatum and substantia nigra of SYN120 mice. These alterations
were accompanied by a significant increase of DAT striatal levels in transgenic animals when compared to wild type
littermates. Our data indicate that, in the early pathogenesis of PD, a-synuclein acts as a fine modulator of the dopaminergic
synapse by regulating the subcellular distribution of key proteins such as the DAT.
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Introduction
Parkinson’s disease (PD) is characterized by a progressive loss of
dopamine (DA) neurons of the nigrostriatal system and by the
presence of Lewy bodies (LB), proteinaceous inclusions mainly
composed by filamentous a-synuclein aggregates [1–3].
Alpha-synuclein is a natively unfolded protein which plays a
central role in the control of dopaminergic neuronal functions
[3;4] and which is thought to be critically implicated in PD
pathophysiology. Indeed, besides the fact that a-synuclein is the
main protein component of LB, genetic studies indicate that
mutations and multiplications of the a-synuclein gene are
responsible for the onset of familial forms of PD. Recent findings
showed that decreased putaminal DA transporter (DAT) binding
and DA deficits occur in patients bearing nigral a-synuclein
burden [5] shading light upon the notion that, in the PD brain, a-
synuclein deposition in the substantia nigra inversely correlates
with striatal DAT functions. This is a relevant observation, as the
DAT acts as a key modulator of dopaminergic signalling by
mediating rapid clearance of DA from the synaptic cleft [6;7]. The
DAT is localized both at synaptic and extra-synaptic sites in cell
bodies and dendrites of dopaminergic neurons of the substantia
nigra, as well as in dopaminergic terminals in the striatum [8;9]. At
these locations, it mediates stimulated and quantal DA reuptake,
thus controlling DA recycling at the synapse as well as the lifetime
of DA spillover [6;10;11]. Therefore, to define whether and how
a-synuclein may affect its function is crucial to unravel the
molecular mechanisms underlying DA-related PD pathophysiol-
ogy. Previous studies have shown that a direct protein-protein
interaction between these two proteins occur [6;12–14]. In
particular, the N-terminus of a-synuclein is known to bind the
C-terminus of the DAT [12;13]. Remarkably, it has been found
that this interaction is essential for the attenuation of DAT activity
mediated by a-synuclein, a function which is thought to be
relevant for the control of DA synaptic tone [13;15;16]. In
particular, it seems that a-synuclein can negatively regulate DAT
activity by tethering the transporter to the microtubular network,
as agents which disrupt microtubular dynamics abolish the
inhibitory effect of a-synuclein upon the DAT [17]. However,
the evidence that a-synuclein is a negative regulator of the DAT
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has been recently brought into question by other findings
showing that a-synuclein knock-out and null mice show reduced
DAT expression and function and a significant increase in basal
DA release [18]. Furthermore, whether the data by Sidhu and
coworkers supported the cause of a neuroprotective role of a-
synuclein through the control of DA influx, Lee and coauthors
[12] found that the formation of a-synuclein-DAT complexes
facilitates the membrane clustering of the DAT, thereby
accelerating cellular DA uptake and DA-induced cellular
apoptosis. Although results from the above cited investigations
are quite contradictory, it has to be taken into account that their
discrepancies may be due to different cellular and animal models
used for the studies. This notwithstanding, since a-synuclein
directly interacts with the DAT and this interaction is known to
modulate DAT functionality, it emerges that pathological
changes, increase and/or aggregation of a-synuclein may fatally
affect nigro-striatal dopaminergic functions by modulating DAT
subcellular localization. Prompted by this hypothesis, we recently
aimed at investigating the mechanisms through which patholog-
ical a-synuclein changes may affect DAT function by using
dopaminergic cellular systems. We found that a-synuclein
aggregation decreases DAT membrane expression and that
DAT and aggregated a-synuclein are colocalized within intracy-
toplasmic inclusions in dopaminergic cells [14]. Furthermore, we
fond that agents which are known to stimulate DAT surface
expression, such as DA D2/D3 receptor agonists or cocaine [19–
22], are able to inhibit the formation of DAT/a-synuclein
immunopositive inclusions and increase both DAT and a-
synuclein membrane expression in dopaminergic cells [14].
These data indicate that a-synuclein and DAT share common
trafficking mechanisms. [14]. Hence, the pathological aggrega-
tion of a-synuclein may alter DA neuron function by affecting
DAT distribution, a concept which is further reinforced by other
recent findings by our group. Indeed, we found the occurrence of
an age-dependent redistribution of other DAT-regulating pro-
teins: synaptic N-ethylmaleimide sensitive fusion attachment
protein receptor proteins (SNAREs), which can mediate the
rapid increase of DAT surface expression [23], in the striatum of
a transgenic mouse line expressing truncated human a-synuclein
(1-120) (SYN120 mice). These mice show an age dependent
deposition of a-synuclein aggregates in nigrostriatal dopaminergic
cells [24], a decrease in striatal DA release and reduced
locomotion, occurring prior to a frank dopaminergic neurode-
generation [24;25]. For these characteristics, the SYN120 mice
represent an ideal model for the study of the a-synuclein-related
pathological changes in the early pathogenesis of PD. Interest-
ingly, in that same research report, we found that the DAT was
also markedly redistributed in the striatum of 12-month-old
SYN120 mice when compared to wild type littermates,
supporting the idea that the pathological deposition of a-
synuclein can critically affect DAT subcellular localization.
We thus aimed at investigating whether the DAT is redistrib-
uted as a consequence of a-synuclein aggregation because of the
direct protein-protein interaction between these two proteins. To
this purpose, we studied the occurrence of changes in the
distribution of the DAT/a-synuclein complexes in the striatum
and substantia nigra of 12-month-old SYN120 transgenic mice
[24;25] by using a technique which allows the visualization of
heteromeric protein complexes: the proximity ligation assay (PLA).
We found a marked redistribution of DAT/a-synuclein complexes
in the transgenic mouse brain. These alterations were accompa-
nied by a significant increase of DAT levels, suggesting that
pathological a-synuclein accumulation is able to modulate both
the levels and the localization of DAT protein.
Methods
1 Cell cultures
Control and dopaminergic differentiated SH-SY5Y cells (SH-
SY5Y+) [14] were used. Briefly, cells were grown to confluence in
complete medium made up by Dulbecco’s modified Eagle’s
medium supplemented with 10% of heat-inactivated new born calf
serum, 100 mg/mL penicillin, 100 mg/mL streptomycin and
0.01 mM non-essential amino acids (Gibco). Cells were maintained
at 37uC in a humidified atmosphere of 5% CO2 and 95% O2.
Differentiation was performed incubating the cells for 3 days in
complete medium supplemented with 10 mM of retinoic acid (RA)
(Sigma-Aldrich) and for the following 3 days in complete medium
containing 80 nM of 12-O-tetradecanoyl-phorbol-13-acetate
(TPA).
2 Glucose deprivation
Glucose deprivation (GD) was performed according to the
protocol described by Bellucci et al., [14] with minor modifica-
tions. Briefly, SH-SY5Y+ cells were incubated for 15 min at 37uC
in Dulbecco’s modified Eagle’s medium containing no glucose
(Sigma-Aldrich) supplemented with 10% of new born calf serum
and 0.01 mM nonessential amino acids (NEAA). Then this
medium was removed and replaced with complete medium for
24 h. For the PLA, cells were fixed in 4% paraformadehyde at
24 h from GD.
3 Generation of SYN120 construct and cell transfection
The cDNA of human truncated SYN120 a-synuclein was
produced as previously described [26]. For cell transfection SH-
SY5Y cells were grown to 60–80% confluency and transfected
with either 5 mg of the SYN120 or 5 mg of the empty vector using
the Lipofectamine 2000 reagent (Invitrogen) acconding to the
manufacturer instructions. The efficiency of transfection was
assayed by Western blotting followed by the densitometric assay of
bands and statistical analysis. A statistically significant increase of
68 % (P ,0.05) of a-synuclein expression was found in the
SYN120 transfected cells when compared to control SH-SY5Y+
cells (please see figure S1A,B for further information).
4 Animals
Mice transgenic for human a-syn(1–120) were produced on a
C57BL/6S background (C57BL/6JOlaHsd, Harlan) which lacks
mouse a-synuclein [24;27]. Transgenic homozygous SYN120,
C57BL/6J and C57/BL6S mice of 12 months of age were used for
fluorescence double labelling and PLA experiments or DAT
semiquantitative determinations. Mice were bred in our animal
house facility. The mice were housed in macrolon cages with ad lib
food and water and maintained on a 12-h light/dark cycle at a
room temperature of 23 uC. All experiments were carried out
according to the Directive 2010/63/EU of the European
Parliament and of the Council of 22 September 2010 on the
protection of animals used for scientific purposes. All experimental
and surgical procedures conformed to the National Research
Guide for the Care and Use of Laboratory Animals and were
approved by the Animal Research Committees of the University of
Brescia (Protocol Permit number 04/10). All efforts were made to
minimize animal suffering, to reduce the number of animals used
and to utilize alternatives to ‘‘in vivo’’ techniques, if available.
Expression of the transgene in SYN-120 mice was assayed by
DNA extraction from tail samples and PCR analysis by using a
couple of primers (59-agggtgattcagaggcaggt-39 and 59-
ctgctccctccactgtcttc-39) recognizing a portion of the rat tyrosine
hydroxylase promoter which is driving the expression of the
DAT/a-Synuclein Redistibution in Transgenic Mice
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SYN120 transgene (please see figure S1C for further information)
as previously described [24].
5 Immunohistochemistry
For immunohistochemistry, SYN120 and control mice were
anesthetized with chloral hydrate (400 mg/kg, i.p.) and were
perfused transcardially with 4% ice-cold paraformaldehyde in
0.1 M phosphate buffer, pH 7.2. After 4 h of postfixation, brains
were put in 18% sucrose for at least 24 h and then 30 mm coronal
sections were cut with a cryostat. Single and double labelling
immunohistochemistry was performed according to previously
described methods [28;29]. The immunostaining intensity of DAT
was analysed as optical density by using the NIH IMAGE J
software (NIH, Bethesda, MD, USA). Ten striatal sections per
animal were selected at 30 mm interval and were analysed and
quantified blinded to the genotypes.
6 ‘‘In situ’’ Proximity Ligation Assay (PLA)
The ‘‘in situ’’ PLA studies on fixed cells and brain tissue were
performed as follows (O-LINK Bioscience, Upsalla, Sweden).
Briefly, fixed cells or brain slices were incubated with blocking
solution for 30 min at 37uC and then with the primary antibodies
recognizing DAT and a-synuclein at 1:200 dilution overnight at
4uC. On the following day, samples were washed in low buffered
Tris Buffered Saline with Tween 20 (TBS-T) that was prepared
according to the O-LINK bioscience recipe. Then, the cells and
brain slices were incubated with the PLA probe solution
(containing the secondary antibodies conjugated with the DNA
probes) for 120 min at 37uC. After the removal of the PLA probe
solution samples were washed in TBS-T and incubated with the
hybridization solution containing oligonucleotides that hybridize
to the PLA probes for 15 min at 37uC. Then the samples were
washed and subsequently incubated in the ligation solution
(containing the DNA ligase which allows the ligation of the
probes and oligonucleotides to form a round circle DNA strand)
for 15 min at 37uC. Subsequently, samples were washed in TBS-T
and incubated with the amplification solution, containing DNA
polymerase for the rolling cyrcle amplification (RCA), at 37uC for
90 min. Finally, the samples were incubated with the detection
stock solution (containing Texas Red labeled oligonucleotides that
hybridize to the RCA product) for 60 min at 37uC, washed in SSC
buffers (made up according to the manufacturer’s recipe) and
ethanol and then mounted and analyzed by means of a confocal
microscope.
7 Western blot studies
For DAT and total a-synuclein extraction striatal brain tissue
from C57BL/6J, C57BL/6S and SYN120 mice were lysed in
TBS+ (50 mM Tris-HCl, pH 7.4, 175 mM NaCl, 5 mM EDTA,
0.1 mM PMSF, 1 mM N-ethylmaleimide, plus complete protea-
some inhibitor mixture; Roche Diagnostics,Mannheim, Germany).
Protein concentration in the samples were measured by using the
Bradford assay (Pierce, Rockford, IL). Equal amounts of proteins
(20–25 mg) were run on 4–12% Nu-PAGE Novex Bis-Tris gels
(Invitrogen, Milan, Italy). Densitometric analysis of bands was
performed by means of Gel Pro Analyzer version 6.0 (MediaCy-
bernetics, Bethesda, MD, U.S.A.). All bands were normalized to
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels as a
control of equal loading of samples.
8 Antibodies
Alpha-synuclein was visualized by using syn-1 (BD-Bioscience,
Milan, Italy) recognizing residues 121–125 of the human form and
residues 91–99 of the human and mouse form [30] of a-synuclein.
Anti-DAT, anti-synapsin Ia/b (Calbiochem, San Diego, CA,
USA) and CREB-2 (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) polyclonal antibodies were used to visualize the respective
substrates.
9 Microscopy
Fixed cells and mouse brain sections were observed by means of
an inverted light/epifluorescence microscope (Olympus IX50;
Olympus, Milan, Italy) or by means of a Zeiss confocal laser
microscope (Carl Zeiss S.p.A., Milan, Italy), with the laser set on
l=405–488–543 nm and the height of the sections scan-
ning= 1 mm. Images (5126512 pixels) were then reconstructed
using LSM Image Examiner (Carl Zeiss S.p.A) and Adobe
Photoshop 7.0 (Adobe system, Mountain View, CA, USA)
software.
10 [3H]-DA uptake assay
[3H]-DA uptake assay was performed on SH-SY5Y+ cells and
SH-SY5Y+ cells subjected to GD. Briefly, the medium was
removed and cells were washed twice with 37uC Krebs-Ringer-
Solution (KRS) (16 mM NaH2PO4, 119 mM NaCl, 4.7 mM
KCl, 1.8 mM CaCl2, 1,2 mM MgSO4, 1,3 mM EDTA, 5,6 mM
Glucose, 1 mM L-Ascorbic Acid, pH 7,4). SH-SY5Y+ cells and
SH-SY5Y+ cells subjected to GD were than incubated in triplicate
at 37uC in KRS in absence or presence of 10 mM cocaine for
5 min. Then, [3H]-DA was added to the medium and incubated
for 15 min at 37uC. The medium was then remuved and the cells
were washed three times with ice-cold KRB. Finally, cells were
collected in NaOH 1N and [3H]-DA was quantified by using
scintillation cocktail in b-counter. Specific [3H]-DA uptake was
calculated as a ratio between % [3H]-DA levels in cell lysates
measured in basal conditions and in the presence of 10 mM
cocaine (please see figure S5 for further information).
11 [3H]-DA release assay
[3H]-DA release was assessed in SH-SY5Y+ cells and SH-
SY5Y+ cells subjected to GD. Briefly, the medium was removed
and cells were washed three times with 37uC Basal-KRS (119 mM
NaCl, 2,5 mM KCl, 2,5 mM CaCl2, 1,3 mM MgSO4, 1 mM
NaH2PO4, 26,2 mM NaHCO3, 10 mM Glucose, 1 mM L-
Ascorbic Acid, pH 7,4). Cells were then pre-loaded with [3H]-DA
for 15 min at 37uC. Later, cells were quikly washed with B-KRS at
37uC and immediately treated with B-KRS or K+-KRS (69 mM
NaCl, 5 M KCl, 2,5 mM CaCl2, 1,3 mM MgSO4, 1 mM
NaH2PO4, 26,2 mM NaHCO3, 10 mM Glucose, 1 mM L-
Ascorbic Acid, pH 7,4) or B-KRS supplemented with 10 mM
tetrodotoxin (TTX). Every 10 min samples were collected for a
total session of 30 minutes. Then, whole medium were picked up,
washed twice and cells were collected in 1N NaOH. [3H]-DA was
quantified by using scintillation cocktail in b-counter. The
percentage of [3H]-DA released in the medium was determined
as a % ratio between the D.P.M assayed in the media end the total
D.P.M. assayed in the cells (released fractions plus cell lysate
fractions, please see File S1 for further information).
12 Statistical analysis
Differences in striatal DAT levels as well as DAT O.D. between
12 month-old C57BL/6J, SYN120 and C57BL/6S mice were
assayed by one-way ANOVA followed by Tukey’s multiple
comparison test. n = 5,6 for each group. Differences between
[3H]-DA uptake (% basal/cocaine ratio) were analyzed by using
the Student’s t-test (n = 8,9 for each group). Differences between %
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[3H]-DA release from SH-SY5Y+ cells and glucose deprived SH-
SY5Y+ cells in basal conditions and after K+ or TTX treatment
were analyzed by two-way ANOVA followed by Bonferroni’s post-
comparison test (n = 7–9 for each group).
Results
1 Detection of DAT and a-synuclein interaction by PLA
‘‘in vitro’’
In order to assess whether DAT and a-synuclein complexes are
detectable by the in situ PLA we used an ‘‘in vitro’’ cell system
which has been extensively characterized by our group: dopami-
nergic differentiated SH-SY5Y (SH-SY5Y+) cells subjected to
glucose deprivation, where we previously demonstrated the
occurrence of DAT interaction with both full length and truncated
a-synuclein [14]. SH-SY5Y+ cells express increased levels of
endogenous DAT and a-synuclein afterwards dopaminergic
differentiation with all-trans-retinoic acid (RA) and 12-O-tetra-
decanoyl-phorbol-13-acetate (TPA) [14;31]. We found that in
these cells, glucose deprivation (GD) stimulated a-synuclein
aggregation and that this event decreased DAT membrane levels,
as the DAT and a-synuclein are co-localized in intracytoplasmic
inclusions following the GD insult [14]. Therefore, this cellular
system possesses ideal characteristics to evaluate whether DAT/a-
synuclein interaction is appreciable ‘‘in situ’’ by the PLA, and
whether alterations in the localization of DAT/a-synuclein
complexes can be visualized by using this method.
The DuolinkTM in situ PLA is capable of detecting protein-
protein interactions in tissue and cell samples prepared for
microscopy [32]. The method is based on the use of two primary
antibodies, raised in different species, that are recognizing the two
proteins of the target interaction. A pair of oligonucleotide labeled
secondary antibodies (PLA probes) is applied on the sample and a
signal is generated only when between the two PLA probes there is
a tight nearness. Indeed, the oligonucleotidic probes-labeled
secondary antibodies are hybridized with two oligonucleotides
which are then ligated into a closed circle when the PLA probes
are in close proximity. This round circle oligonicleotide sequence
is then amplified generating a concatemeric product extending
from the oligonucleotide arm of the PLA probe. Subsequently, this
product is hybridized with a mixture of fluorescent labeled probes
thus allowing the amplification of the signal. As a consequence a
single protein-protein interaction can be visualized in situ as a red
dot by fluorescence microscopy. Hence, this technology can detect
any antigen with proximate epitopes at the single molecule level
[32;33].
We thus investigated DAT/a-synuclein interactions in the SH-
SY5Y+ dopaminergic cell model. We found that SH-SY5Y+ cells
showed a diffuse PLA-positive signal, indicative of DAT/a-
synuclein interaction. In particular, the DAT/a-synuclein PLA-
positive signal was mainly localized at the periphery of the cell
(fig. 1A) in line with our previous findings showing that these
proteins were mainly localized on the cell membrane in the control
SH-SY5Y+ cells [14]. Furthermore, in agreement with the
previous observations showing that GD was able to induce the
formation of DAT/a-synuclein-positive inclusions in SH-SY5Y+
cells [14], we found the presence of an intense PLA-positive signal
into intracytoplasmic dot-like inclusions (fig. 1B) in the glucose
deprived SH-SY5Y+ cells, thus confirming that the DAT is
retained into intracytoplasmic inclusions following a-synuclein
aggregation as these two proteins directly interact.
Then, we aimed at evaluating whether the overexpression of
human c-terminally truncated (1–120) a-synuclein SYN120, which
is expressed by the SYN120 transgenic mice, may affect the
subcellular localization of DAT/a-synuclein complexes. To date,
about 15% of a-synuclein in LB is truncated [34–37]. The
pathological c-terminal cleavage of a-synuclein confers to the
protein an high aggregation propensity [38;39]. This form of a-
synuclein derives from the caspase like 20 S proteasomal
degradation of unstructures full length intracellular a-synuclein
[36;38] and it is believed to be implicated in the initiation and
progression of the aggregation process of full length a-synuclein as
Figure 1. Detection of DAT and a-synuclein interaction by PLA ‘‘in vitro.’’ A: DAT and a-synuclein PLA in control SH-SY5Y+ cells. Please note
a diffuse PLA-positive red signal. B: DAT and a-synuclein PLA in glucose deprived SH-SY5Y+ cells. Please note the presence of a PLA-positive inclusion
(indicated by the arrow) within one of these cells. C: DAT and a-synuclein PLA in control SH-SY5Y+ cells. The PLA signal is weak and diffuse in these
cells. D: DAT and a-synuclein PLA in SYN120-transfected SH-SY5Y+ cells. Please note the presence of an inclusion (indicated by the arrow) within one
of these cells. E: synapsin I and a-synuclein PLA on pcDNA1-transfected SH-SY5Y cells. Please note that the PLA signal appears to be weak and
diffused. F: synapsin I and a-synuclein PLA in SYN120-transfected SH-SY5Y+ cells. Some positive dots (indicated by the arrows) were visible within
these cells. G: CREB-2 and a-synuclein PLA in control SH-SY5Y+ cells. No PLA signal was detected in these cells, which is indicative of the absence of
CREB-2 and a-synuclein interaction. H: CREB-2 and a-synuclein PLA in glucose deprived-SYN120-transfected SH-SY5Y+ cells. No PLA signal is visible.
I-L: Single labeled cells were used as negative controls for PLA experiments. I: a-synuclein antibody; J: DAT antibody; K: synapsin I antibody; L: CREB-2
antibody. Scale bar: 15 mm for A–L.
doi:10.1371/journal.pone.0027959.g001
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it can seed the aggregation of the wild type form of the protein
[36–38;40;41]. We thus investigated whether transfection of the
human SYN120 a-synuclein construct, which coincides with the
formation of intracellular aggregates ‘‘in vitro’’ [26], may affect the
subcellular localization of DAT/a-synuclein complexes visualized
by the in situ PLA. We found the presence of dot-like DAT/a-
synuclein PLA-positive intracytoplasmic inclusions in the
SYN120-transfected SH-SY5Y+ cells (fig. 1D). Similarly to the
control SH-SY5Y+ cells, the cells which were transfected with the
empty pcDNA1 vector showed a diffuse PLA-positive signal in
proximity of the cell membrane, but no inclusions. Thus, our
findings indicate that the overexpression of the (1–120) c-
terminally truncated form of a-synuclein induces the formation
of intracellular inclusions containing the DAT, and is consequently
able to alter the subcellular distribution of the DAT.
To confirm that DAT levels on the plasma membrane were
decrease in the SH-SY5+ cell subjected to glucose deprivation
and in the SYN120-trensfected cells we performed immunopre-
cipitation experiments (please see File S1 for further information)
using plasma membrane extract from control, glucose deprived-
and SYN120-transfected SH-SY5Y+ cells. Our results showed
that DAT and a-synuclein levels on the plasma membrane in the
SH-SY5Y+ cells subjected to GD and transfected with the
SYN120 construct were lower when compared to control cells
(figure S2A).
In order to confirm the specificity of detection of DAT and a-
synuclein interaction by the PLA, we performed a panel of control
experiments to investigate whether synapsin I, a synaptic protein
which is known to be part of DAT [42] and a-synuclein [43]
proteome and which can also directly interact with a-synuclein in
SH-SY5Y+ cells (figure S2B), may also be found in close proximity
to a-synuclein within intracellular aggregates when this cellular
system is transfected with the SYN120 construct. In particular, we
aimed at evaluating whether a-synuclein/synapsin I interaction
can be visualized in situ by the PLA and whether the distribution of
this complex is also appreciable by the PLA. We were able to
detect a dot-like positive signal, indicative of the close proximity of
truncated a-synuclein and synapsin I within intracellular inclu-
sions, in the SYN120-transfected SH-SY5Y+ cells (fig. 1F). In the
control SH-SY5Y+ cells transfected with the empty pcDNA1
vector only a slightly detectable and diffuse PLA signal was present
(fig. 1E). These observations confirm that the PLA signal is capable
of detecting specific protein-protein interactions and indicate that
a-synuclein aggregation may affect the correct subcellular
distribution of other protein member of the DAT/a-synuclein
proteome.
To further confirm that our PLA results were indicative of
protein proximity we performed experiments to verify the absence
of protein-protein interactions between a-synuclein and CREB-2,
a transcription factor which didn’t co-immunoprecipitate with a-
synuclein in SYN120-transfected glucose deprived SH-SY5Y+
cells (please see figure S2C for further information). No interaction
between a-synuclein and CREB-2 was detected in the glucose
deprived SYN120-transfected SH-SY5Y+ cells (fig. 1H) where the
GD insult is able to induce CREB-2 production [26] as in the
control SYN-120-transfected SH-SY5Y+ cells (fig. 1G) which only
express low levels of CREB-2 [26].
Finally, we performed control experiments by incubating
SYN120-transfected SH-SY5Y+ cells with only one of the
antibodies that we used for the previously describe PLA
experiments. No PLA-positive signal was detected in the samples
which were incubated with the sole anti-syn-1 (fig. 1I), anti-DAT
(fig. 1J), anti synapsin-I (fig. 1K) or anti-CREB-2 (fig. 1L)
antibodies.
Overall, these findings confirm that a-synuclein aggregation
affects the proper localization of the DAT, and that the PLA is a
useful technique to specifically visualize DAT/a-synuclein com-
plexes and their subcellular distribution. In particular, we found
that the DAT is retained within a-synuclein intracytoplasmic
inclusions following the pathological aggregation of this latter, and
these inclusions are visible by using the PLA.
2 DAT and a-synuclein labeling in the striatum and
substantia nigra of wt and tg mice
The above described results prompted us to investigate whether
the pathological aggregation of a-synuclein may alter the correct
distribution of the DAT ‘‘in vivo’’. We thus performed in situ PLA
studies in a transgenic mouse line displaying a-synuclein
aggregation into dopaminergic neurons of the substantia nigra:
the SYN120 mice. This mouse model [24;25] express human c-
terminally truncated (1–120) a-synuclein under the guidance of the
rat TH promoter on an endogenous a-synuclein null C57BL/6S
background [27]. At 12-months of age, the SYN120 transgenic
mice show an age dependent decrease in striatal DA release and
reduced locomotion, similar to PD [24;25], which are indicative of
nigro-strital dopaminergic dysfunctions. To date, in a recent
report, we already reported a marked redistribution of DAT
protein in the striatum of this mice [25]. We thus considered that
12 month-old SYN120 mice represent an ideal model to
investigate the redistribution of DAT/a-synuclein complexes.
Twelve month-old C57BL/6J mice, expressing endogenous a-
synuclein, and C57BL/6S littermates [27] which are null for
endogenous a-synuclein, were used as controls.
Firstly, we investigated both DAT and a-synuclein localization
in the striatum and substantia nigra of 12 month old SYN120,
C57BL/6J and C57BL/6S mice by fluorescence double labeling
immunohistochemistry. We found that DAT and a-synuclein
labeling almost completely co-localized in striatal dopaminergic
terminals (arrows in fig. 2A–C) of the C57BL/6J mice, although a
small portion of DAT staining, that didn’t co-localize with a-
synuclein, was diffusely distributed throughout the striatum fig. 2B–
C. As in the C57BL/6J mouse brain, in the striatum of the
SYN120 mice DAT and a-synuclein labeling partially colocalized.
However, in these mice the distribution of DAT/a-synuclein
labeling appeared to be different. Indeed, DAT and a-synuclein
clustered in big dot-like inclusions (fig. 2D–F arrowhead) and
neurite-like structures (fig. 2D–F, arrow) that were reminiscent of
the a-synuclein-positive dots and of the Lewy neurites (LN) which
have been described in the PD brain [44–46]. In the striatum of
the C57BL/6S a-synuclein null mice we didn’t observe a-
synuclein staining and the DAT labeling displayed a distribution
that was similar to that observed in the striatum of C57BL/6J mice
(Fig. 2G–I).
In the substantia nigra of C57BL/6J mice, DAT and a-
synuclein displayed a punctuate staining which appeared to be
distributed on the cell membrane of dopaminergic neurons
(Fig. 3A–C) in agreement with previous observations showing
that DAT staining in this area of the mouse brain is mainly
present on the cell membrane of dopaminergic neurons [9;47].
This observation was confirmed by immunofluorescent experi-
ments which showed that DAT localization was similar to that of
the membrane associated protein APP (please see figure S3 for
further information). We also found that, as observed in the
striatal sections, DAT and a-synuclein labellings almost com-
pletely colocalized (fig. 3C). In the substantia nigra of the
SYN120 mice we observed that several neurons showed the same
pattern of distribution of DAT and a-synuclein staining that we
observed in the C57BL/6J mice, as they co-localized in dot-like
DAT/a-Synuclein Redistibution in Transgenic Mice
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structures on the plasma membrane (indicated by the yellow
arrow in fig. 3D–F). However, in the neurons which contained a-
synuclein inclusions, DAT staining was absent on the plasma
membrane but it was intense in correspondence of the a-
synuclein-positive aggregates in the cytoplasm (arrowhead) and in
the processes (white arrows) as showed by representative
photomicrographs in figure 3D–F. This distribution is reminis-
cent of the intracellular localization of DAT/a-synuclein
inclusions that we previously described in glucose deprived
dopaminergic cells [14]. Remarkably, in the SYN120 transgenic
mice, a-synuclein labeling, although very intense in correspon-
dence of intracellular inclusions, was still abundant on the plasma
membrane, in agreement with previous findings indicating that
truncated a-synuclein has an high propensity to interact with
plasma membranes as it easily adopts an a-helical structure [37].
Finally, in the substantia nigra of the C57BL/6S mice a-
synuclein labeling was absent (fig. 3G–I) and DAT staining was
similar to that observed in the C57BL/6J wt mice as it displayed
a punctuate distribution (Fig. 3H–I). These findings indicate that
the subcellular localization of the DAT mostly reflected that of a-
synuclein although a portion of these protein didn’t co-localize,
thus indicating that an elevated quote of these two proteins
directly interact.
3 The localization of DAT and a-synuclein PLA signal was
altered in the striatum and substantia nigra of SYN120
transgenic mice
To confirm the occurrence of DAT/a-synuclein interaction in
the SYN120 and C57BL/6J mice we performed co-immunopre-
cipitation experiments (please see File S1 for further information)
by using striatal protein extracts. C57BL/6S a-synuclein null mice
were used as negative controls. We found that a-synuclein was
present in the DAT-immunoprecipitates of the SYN120 and
C57BL/6J mice, while in the striatum of C57BL/6S mice no a-
synuclein was detected (figure S4).
To visualize alterations in the distribution of DAT and a-
synuclein complexes in the striatum and substantia nigra of the 12
month-old C57BL/6J and SYN120 mice we used the ‘‘in situ’’
PLA. Again, the C57BL/6S mouse line lacking a-synuclein was
used as negative control.
We found the occurrence of DAT and a-synuclein interactions
in little dot-like structures (fig. 4A, D) in the C57BL/6J mice. In
the striatum of the SYN120 mice DAT and a-synuclein PLA
signal displayed an altered distribution as it appeared to be
condensed in bigger aggregates (fig. 4B, E). In the a-synuclein
null mice we didn’t observe the PLA signal in the striatum,
confirming the absence of the interaction between the proteins
(fig. 4C,F).
In the substantia nigra of the C57BL/6J wt mice an evident
PLA-positive signal indicative of DAT and a-synuclein interaction
was present. In particular, the PLA signal displayed a punctuate
staining which followed the same localization of DAT and a-
synuclein that we previously visualized by fluorescence immunois-
tochemistry (fig. 5A, D).
In the substantia nigra of the SYN120 mice the PLA signal
clustered in big inclusions (fig. 5B, E). Furthermore, as observed by
fluorescent staining, a small proportion of punctuate signal
(indicated by the arrowheads in fig. 5B), reminiscent of the dot-
like morphology of Lewy neurites which have been observed in the
PD brain [44–46;48] was also detectable in the tissue.
In the substantia nigra of the a-synuclein null mice no PLA
positive signal was detected, indicating the absence of protein-
protein interaction between DAT and a-synuclein (fig. 5C,F).
Figure 2. DAT and a-synuclein double staining in the striatum. DAT (green signal) and a-synuclein (red signal) double staining in the striatum
of C57BL/6J (panel A–C), SYN120 (panel D–F) and C57BL/6S (panel G–I) mice. Panels C, F, I show the merges of DAT and a-synuclein labeling. Please
note the marked redistribution of both DAT and a-synuclein immunolabeling in the SYN120 mice. In the C57BL/6S mice which didn’t express
a-synuclein, DAT distribution was similar to that observed in the C57BL/6J mice. Scale bar: 60 mm for A–I.
doi:10.1371/journal.pone.0027959.g002
DAT/a-Synuclein Redistibution in Transgenic Mice
PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e27959
Figure 3. DAT and a-synuclein double staining in the substantia nigra. DAT (green signal) and a-synuclein (red signal) double staining in the
substantia nigra of C57BL/6J (panel A–C), SYN120 (panel D–F) and C57BL/6S (panel G–I) mice. Panels C, F and I show the merges between DAT and a-
synuclein immunolabelings. Please note that DAT and a-synuclein co-localized in dot-like clusters in the C57BL/6J mice. In the SYN120 mice DAT
labeling was concentrated in big intracellular inclusions and within neuronal processes (arrows) and cell bodies (arrowhead) together with truncated
a-synuclein, although some cells showed the same clustered co-localization of DAT and a-synuclein that we observed in the C57BL/6J mice (yellow
arrow). In the C57BL/6S mice DAT distribution in the substantia was similar to that observed in the C57BL/6S mice. Scale bar: 40 mm for A–I.
doi:10.1371/journal.pone.0027959.g003
Figure 4. DAT and a-synuclein PLA in the striatum. DAT and a-synuclein PLA in the striatum of C57BL/6J (panel A) SYN120 (panel B) and
C57BL/6S (panel C) mice. Panels D, E and F show higher magnifications of the squares in panels A, B and C, respectively. Please note that in the
SYN120 mice the PLA signal (indicated by the arrows) displayed a more condensed distribution with respect to the C57BL/6J mice. In the C57BL/6S
mice, which were lacking a-synuclein, no PLA signal was detected. Scale bars: A = 60 mm for A–C; D= 10 mm for D–F.
doi:10.1371/journal.pone.0027959.g004
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4 DAT levels in the striatum of transgenic and control
mice
DAT levels in the striatum were assayed by semiquantitative
analysis of DAT immunopositive bands from WB experiments
(fig. 6). We found that in the 12 month-old SYN120 mice DAT
levels were significantly increased respect to the C57BL/6J mice (1
+59%; P ,0.001) and to the a-synuclein null mice (* +103%; P
,0.001). Remarkably, DAT levels in the C57BL/6S mice were
significantly lower (244%, P ,0.01) when compared to the
C57BL/6J mice.
To confirm these findings we also quantified DAT immunore-
activity by using an image analysis software. We found a
significant increase of % DAT density in the striatum of
SYN120 transgenic mice when compared to the C57BL/6J
(+95%, P ,0.001) or to the C57BL/6S (+129%, ,0.001) mice.
Conversely, DAT density was significantly decreased in the
striatum of C57BL/6S mice (234%, P ,0.05) with respect to
C57BL/6J mice.
5 Functional studies
To evaluate whether the formation of DAT-a-synuclein
complexes can coincide with a reduction of DA uptake we
assayed % [3H]-DA uptake by SH-SY5Y+ and glucose deprived
SH-SY5Y+ cells (fig. 7A). We found that in the SH-SY5Y+
subjected to GD the [3H]-DA uptake ratio was significantly lower
when compared to untreated cells (* 242.77% P ,0.05). The
specificity of DA uptake by the DAT was assayed by using cocaine
(please see figure S5A for further information).
Finally we evaluated % [3H]-DA release from SH-SY5Y+ and
glucose deprived SH-SY5Y+ cells (Fig. 7B). [3H]-DA levels in the
media, were normalized to the initial [3H]-DA quote which was
taken by the cells (please see figure S5B for further information),
and expressed as % changes. We found a significant reduction
of extracellular [3H]-DA levels after 30 minutes in control
SH-SY5Y+ cells (* 219%, P ,0.01, Bonferroni’s post comparison
test) when compared to glucose deprived SH-SY5Y+ cells. The
difference of [3H]-DA levels after 30 minutes was even higher
between K+-treated SH-SY5Y+ and K+-treated-glucose deprived-
SH-SY5Y cells (# 224%, P ,0.01, Bonferroni’s post comparison
test). TTX treatment induced a significant block of [3H]-DA
release in both SH-SY5Y+ (1 P ,0.05 Bonferroni’s post-
comparison test) and glucose deprived SH-SY5Y+ cells (u P
Figure 5. DAT and a-synuclein PLA signal in the substantia nigra. DAT and a-synuclein PLA in the substantia nigra of C57BL/6J (panel A, D)
SYN120 (panel B, E) and C57BL/6S (panel C, F) mice. Panels D, E and F show higher magnifications of the squares in panels A, B and C, respectively. In
the C57BL/6J mice PLA-positive blobs were present while in SYN120 mice the PLA signal was condensed in big dots. In the C57BL/6S mice no PLA
signal was detected. Scale bars: A = 60 mm for A–C; D= 20 mm for D–F.
doi:10.1371/journal.pone.0027959.g005
Figure 6. DAT levels in the striatum. A: Semiquantitative analysis of
DAT levels in the striatum of C57BL/6J (white bars), SYN120 (black bars)
and C57BL/6S (striped bars) mice. Please note the statistically significant
increase of DAT levels in the SYN120 transgenic mice when compared
to C57BL/6J and C57BL/6S wild type mice. B: Quantitative analysis of
DAT immunoreactivity (% optical density) in the striatum of SYN120,
C57BL/6J and C57BL/6S mice.
doi:10.1371/journal.pone.0027959.g006
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,0.05 Bonferroni’s post-comparison test). Finally, we performed
control experiments by evaluating basal, K+-stimulated, TTX-
blocked as well as K+ and TTX treated SH-SY5Y and glucose
deprived-SH-SY5Y cells in the presence of the DAT blocker
cocaine (please see File S1 for further information). Remarkably,
we found that glucose deprived SH-SY5Y+ cells showed reduced
[3H]-DA release and that cocaine abolished the time dependent
decrease of extracellular [3H]-DA levels in the media of SH-
SY5Y+ cells (figure S5C).
Discussion
Our study showed the occurrence of a redistribution of DAT/a-
synuclein complexes visualized in situ by PLA in synaptic terminals
as well in the cell soma of dopaminergic nigrostriatal neurons of
the SYN120 transgenic mouse model. We also found a significant
augment of striatal DAT levels, thus indicating that both DAT
expression and distribution are crucially affected by the synaptic
accumulation of the pathological C-terminally truncated (1–120)
form of a-synuclein. Indeed, the DAT co-localized and interacted
with a-synuclein into intracellular inclusions following the
pathological aggregation of this latter in dopaminergic neurons
of the nigrostriatal system of 12-month-old SYN120 transgenic
mice. In agreement with previous observations showing that the
residues 58–107 of a-synuclein are directly involved in the
interaction with the C-terminus of the DAT [15], our data
confirm that the carboxy-terminal truncation of a-synuclein
doesn’t alter the ability of the protein to bind the DAT.
Remarkably, our data showed a frank redistribution of DAT/a-
synuclein PLA-positive complexes both in striatal terminals and in
neuronal cell bodies of nigral dopaminergic neurons, indicating
that a-synuclein may likely play a role, not only in the control of
DAT trafficking in striatal synapses, but also in regulating DAT
localization within the somatodendritic compartment of dopami-
nergic cells. These observations are in line with our previous
findings showing that glucose deprivation, an insult which
stimulates a-synuclein insoluble aggregation, induced the forma-
tion of DAT/a-synuclein-immunopositive inclusions within the
cell bodies and processes of primary mouse mesencephalic
dopaminergic neurons [14]. In the substantia nigra, the DAT
can be specifically transported into dendrites. In particular, it is
involved in the tuning of intracellular and extracellular DA levels
in the somatodendritic compartment [49]. Therefore, our
observations indicate that, whether a-synuclein aggregation may
compromise DAT trafficking, this event may lead to alterations in
somatodendritic DA release. As DA release by the somatodentritic
compartment is a phenomenon that can usually facilitate motor
functions in physiological conditions by mechanisms that may act
independently from axon terminal DA release in the striatum, it
may be feasible that one of the consequences of a-synuclein
aggregation-dependent DAT redistribution within the dopami-
nergic neurons may be the impairment of this process. Hence,
DAT redistribution may affect both striatal synaptic and
somatodendritic DA release. This hypothesis is reinforced by the
fact that we found that glucose deprived SH-SY5Y+ cells showed a
reduction of [3H]-DA uptake and that this event was paralleled by
Figure 7. [3H]-DA uptake and [3H]-DA release in control and glucose-deprived SH-SY5Y+ cells. A: The graph is showing [3H]-DA uptake
by SH-SY5Y+ and glucose deprived SH-SY5Y+ cells (SH-SY5Y+ GD). B: The graph is showing [3H]-DA release by SH-SY5Y+ and SH-SY5Y+ GD cells in
basal contition and after TTX block or 50 mM K+ (K) treatment.
doi:10.1371/journal.pone.0027959.g007
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a time-dependent accumulation of [3H]-DA in the medium of
these same cells. Furthermore, we found that [3H]-DA release,
evaluated in the presence of the DAT blocker cocaine increased in
a time dependent manner in the SH-SY5Y+ cells. Conversely, in
the glucose deprived cells cocaine did not induced a time-
dependent increase in [3H]-DA release.
In line with results from a recent research report showing that
density of DAT immunoreactivity in the dorsal striatum is
significantly lower in the C57BL/6S mice when compared to
C57BL/6J mice [18] we found that DAT levels were reduced in
the striatum of C57BL/6S mice. Furthermore, our data showed
that the overexpression of the truncated form of a-synuclein
altered the striatal levels of the DAT. Indeed, we found a
significant increase in DAT levels in the brain of the SYN120
mice when compared to the C57BL/6J and C57BL/6S mice,
indicating that whether the lack of a-synuclein coincides with a
reduction of DAT, the overexpression of its c-terminally
truncated form induces a significant augment of DAT expression.
However, it has to be considered that 12-month-old SYN120
mice show a significant reduction of both basal and depolariza-
tion-dependent striatal DA release as well as a decrease of DA
metabolites [25] which is likely indicative of a reduction of DA
turnover. Hence, we can’t exclude that the increased expression
of the DAT may be the consequence of compensatory
mechanisms related to these alterations. Nonetheless, it could
be feasible that this phenomenon may further exacerbate the
formation of insoluble intracellular inclusions as the DAT is
retained together with aggregated a-synuclein within synaptic
terminals and neuronal cells. To date, it has been reported that
DAT-positive neurons of the nigrostriatal system express low a-
synuclein levels, suggesting that nigral dopaminergic neurons may
be particularly vulnerable to variations of a-synuclein levels [50].
This is supported by other findings showing that siRNA
knockdown of a-synuclein induced a significant 50% decrease
of DAT activity in neuroblastoma cells [51] like the knock out of
a-synuclein significantly decreases striatal DAT expression [18]
and DA uptake. Thus, a-synuclein may act by promoting DAT
expression in physiological conditions, although recent evidence
has demonstrated that overexpression of a-synuclein is able to
decrease the rate and magnitude of DAT-mediated substrate
uptake [52]. Noteworthy, the data collected in the present study
indicate that DAT expression and subcellular distribution may
also be altered as a consequence of a-synuclein aggregation.
Indeed, our findings suggest that the aggregation of a-synuclein
could impair the correct trafficking of the DAT to synaptic sites.
This hypothesis is supported by the fact that we recently
demonstrated that a-synuclein and the DAT share common
trafficking mechanisms and that as a consequence of the critical
interaction between these proteins, agents which are able to
modulate DAT trafficking to the plasma membrane, such as DA
D2/D3 receptor agonists and cocaine, may also indirectly
regualte a-synuclein localization [14;17]. On this line, it has
been shown that disruption of the interaction of a-synuclein with
microtubules enhances the cell surface recruitment of the DAT
[17]. Remarkably, besides binding to tubulin [53], the main
constituent of the microtubular network, a-synuclein can also
interact with- and modulate the dynamics of actin cytoskeleton in
physiological conditions [54;55], thus rendering it possible that its
aggregation may consequently alter various synaptic processes.
Hence, a-synuclein aggregation may result in a decrease of a-
synuclein actin-binding properties, a phenomenon which may
then alter actin cytoskeleton dynamics thus affecting DAT
trafficking to synaptic sites. In this scenario, it could be feasible
that a loss of the correct assembly of the cytoskeleton may lead to
the critic accumulation of other synaptic vesicle associated
proteins. In agreement with this hypothesis, we previously
described the occurrence of a substantial redistribution of
SNAREs in striatal synapses of SYN120 transgenic mice. It has
to be taken into account that although the DAT has not been
directly demonstrated to be present in vesicles, its membrane
content is inhibited by toxins which are able to inhibit SNAREs
function, while it is enhanced by SNAREs overexpression [23;56–
58], thus the possibility that DAT redistribution could be also a
consequence of SNAREs redistribution can’t be excluded.
Finally, another important clue to take into account is that
Afonso-Oramas and coworkers [59] recently showed that the
DAT can be either redistributed from the plasma membrane to
the endoplasmic-reticulum-Golgi compartment or persistently
down regulated in response to slight or substantial dopaminergic
lesions, respectively. Remarkably, from our previous findings we
know that dopaminergic neurons of the nigrostriatal system in the
12 month-old SYN120 transgenic mice are hypofunctioning but
do not degenerate as we couldn’t find activation of the apoptotic
or autophagic pathways or a decrease in TH levels [24;25]. This
notwithstandings, we recently found that, in the brain 12 month-
old SYN120 transgenic mice, the dopaminergic nigrostriatal
neurons bearing a-synuclein inclusions show the activation of
the unfolded protein response (UPR), an endoplasmic reticulum
stress-related pathway which is induced by a-synuclein accumu-
lation within the endoplasmic reticulum itself [26]. To date, it has
been shown that prolonged activation of the UPR usually
coincides with a block of endoplasmic reticulum-Golgi traffic
and with the inhibition of the trans-Golgi network (TGN), a system
which is crucially implicated in synaptic vesicles biogenesis and
repackaging. In this scenario, whether the trans-Golgi network is
impaired by the a-synuclein-induced UPR activation, the transfer
of a-synuclein from the cell body to the synapse which is mediated
by the fast axonal transport [43], vehiculating Golgi-derived
vesicles containing neurotransmitters or associated proteins to the
axolemma, may be critically reduced. This may lead to a stall of a-
synuclein-related synaptic vesicle pools, with a substantial
disassembling of the synaptic proteome. Therefore, we can’t
exclude that the redistribution of synaptic proteins observed in the
striatum of these mice may be a consequence of these events.
However, these aspects still need to be investigated.
Conclusions
Taken together, our observations indicate that, in the early
pathogenesis of PD a-synuclein accumulation may induce a
redistribution of the DAT. Indeed, in line with the idea that a-
synuclein is a causative agent for PD [60], we found that this
protein plays a pivotal role in the regulation of this key protein
involved in the function of dopaminergic synapses of the
nigrostriatal system. These findings point out that a-synuclein
accumulation can contribute to the onset of synaptic dysfunctions
in dopaminergic neurons of the nigrostriatal system in the PD
brain.
Supporting Information
Figure S1 A: Representative photomicrograph showing a-
synuclein expression (SYN-1 antibody) in SH-SY5Y+ cells, SH-
SY5Y+ cells subjected to GD and SYN120-transfected as well as
pcDNA1-transfected SH-SY5Y+ cells. B: The table is showing the
quantitative analysis of the SYN-1-immunopositive bands in SH-
SY5Y+ cells, SH-SY5Y+ cells subjected to GD and SYN120-
transfected as well as pcDNA1-transfected SH-SY5Y+ cells. Please
note the statistically significant increase (+1.4, P,0.01) of the
DAT/a-Synuclein Redistibution in Transgenic Mice
PLoS ONE | www.plosone.org 10 December 2011 | Volume 6 | Issue 12 | e27959
SYN120/SYN140 ratio in the SYN120-transfected SH-SY5Y+
cells.
(TIF)
Figure S2 Western blotting and immunoprecipitation
studies on SH-SY5Y+ cells. 60 mg of proteins were loaded
in the input and 150 mg of proteins were used for the
immunoprecipitation experiments. A: Representative im-
munoblotting showing DAT immunoprecipitation from plasma
membrane extract of control, glucose deprived (SH-SY5Y+ GD)
and SYN120-transfected (SH-SY5Y+ SYN 120). Amyloid precur-
sor protein (APP) inputs from the respective membrane extracts
were used as a control. B: Representative immunoblotting showing
that DAT and synapsin 1 co-immunoprecipitated with a-synuclein
in SH-SY5Y+ cells. C: Blots are showing that although CREB-2
was induced in SYN120-transfected glucose deprived-SH-SY5Y+
cells, it didn’t co-immunoprecipitate with a-synuclein.
(TIF)
Figure S3 Double immunofluorescent staining for DAT
(panels B, F, J) and APP (A, E, I) in the substantia nigra
of C57BL/6J, SYN120 and C57BL7/6S mice. Please note
that in the substantia nigra of the C57BL/6J and C57BL/6S mice
DAT labelling showed a distribution that was similar to that of
APP, while in the SYN120 transgenic mice it was mainly located
in intracellular inclusions. Scale bar: A=40 mm for A-L.
(TIF)
Figure S4 Western blotting and immunoprecipitation
studies on 12 month old SYN120, C57BL/6J and C57BL/
6S mice. 30 mg of proteins were loaded in the input and 100 mg
of proteins were used for the immunoprecipitation experiments. A:
Representative immunoblotting showing that the DAT co-
immunoprecipitated with truncated a-synuclein in the striatum
of 12 month old SYN120 and C57BL/6J mice. C57BL/6S mice
were used as negative controls for co-immunoprecipitation.
(TIF)
Figure S5 A: [3H]DA uptake in SH-SY5Y+ and glucose
deprived-SH-SY5Y+ cells in basal conditions and after cocaine
treatment. Please note that the glucose deprived cells showed a
statistically significantly decreased [3H]DA uptake (* 272 %, P
,0.01, Bonferroni’s post-comparison test) when compared to
control SH-SY5Y+ cells. Cocaine treatment significantly blocked
[3H]DA uptake in SH-SY5Y+ (# 2105 %, P ,0.001,
Bonferroni’s post-comparison test) and SH-SY5Y+ cells subjected
to GD (1 236 %, P ,.01, Bonferroni’s post-comparison test). B:
% [3H]DA levels in the SH-SY5Y+ cell media, cell lysates and
total values (indicative of the sum of [3H]DA levels in media and
lysates) in SH-SY5Y+ and glucose deprived SH-SY5Y cells in
basal conditions and after K+ and TTX treatment. C: [3H]DA
release from SH-SY5Y+ and glucose deprived-SH-SY5Y+ cells in
basal conditions and after K+ and/or TTX treatments. Please
note that basal [3H]DA release from SH-SY5Y+ cells was higher
than that observed in the glucose-deprived cells. Furthermore,
[3H]DA release in the presence of cocaine was unable to induce a
time-dependent increase in [3H]DA release in the glucose
deprived cells.
(TIF)
File S1 Supplementary information concerning the
methods used for immunoprecipitation studies and for
assaying [3H]DA release in the presence of cocaine.
(DOC)
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